FDA Variance Approval Letter

The U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health (CDRH), has issued a variance approval letter to Richard Lathrop. The document, dated March 13, 2026, is a formal notification regarding a variance. While the full content is restricted due to personally identifiable information, a redacted version is available, indicating a specific approval has been granted.

This notice serves as an official communication from the FDA. Regulated entities, particularly those involved in drug manufacturing or medical device development, should note this approval as it may pertain to specific product pathways or regulatory exceptions. No immediate compliance actions are mandated by this notice itself, but it signifies a regulatory decision that could impact ongoing product development or market access for the recipient.